title: Ivabradine improves all aspects of quality of life assessed with the 36-item short form health survey in subjects with chronic ischemic heart disease compared with beta-blockers.
abstract: No published studies have evaluated quality of life (QOL) with the 36-item Short Form Health Survey (SF-36) in subjects with chronic stable angina pectoris (CSAP). We evaluated whether a 1-month treatment with 10 mg ivabradine (IVA) or β-blockers (bisoprolol 2.5 mg/day, carvedilol 12.5 mg/day, atenolol 50 mg/day) improves the QOL in patients with CSAP. The SF-36 was administered to 238 patients randomized in two groups. QOL and heart rate (HR) results after 1 month of therapy with IVA and β-blockers (T1) were compared with basal values (T0). Treatments in both groups significantly reduced HR (-11 bpm at T1 compared with T0 in the IVA group, -7 bpm at T1 compared with T0 in the β-blocker group), but IVA demonstrated a more significant (p < 0.001) reduction in HR than β-blocker treatment (p < 0.01). We observed a significant improvement in all QOL dimensions in the group treated with IVA, in particular in the sections regarding physical functioning, physical role, and general health (p < 0.001). In the group treated with β-blockers, we found statistically significant improvement only in the physical functioning and physical role sections (p < 0.01). With β-blocker treatment, many questionnaire sections showed no statistically significant improvement (body pain, social functioning, emotional role, and mental component summary). IVA treatment significantly improves all aspects of QOL in patients with CSAP, unlike β-blocker treatment. This improvement is associated with a greater reduction in HR.
authors.affiliation: Cardiology Unit, San Camillo de Lellis Hospital, Manfredonia, Italy. griccioni@hotmail.com
authors.forename: G
authors.initials: G
authors.lastname: Riccioni
authors.forename: G
authors.initials: G
authors.lastname: Prencipe
authors.forename: A
authors.initials: A
authors.lastname: Benvenuto
authors.forename: L
authors.initials: L
authors.lastname: Masciocco
authors.forename: S
authors.initials: S
authors.lastname: Ventra
authors.forename: U
authors.initials: U
authors.lastname: Rizzo
authors.forename: C
authors.initials: C
authors.lastname: Russi
authors.forename: G
authors.initials: G
authors.lastname: Speziale
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D060050:Angina, Stable / Q000188:drug therapy*; D001262:Atenolol / Q000627:therapeutic use; D001552:Benzazepines / Q000627:therapeutic use*; D017298:Bisoprolol / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D005260:Female; D006306:Health Surveys; D006801:Humans; D000077550:Ivabradine; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use; D011788:Quality of Life
chemical_list: D000319:Adrenergic beta-Antagonists; D001552:Benzazepines; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D000077550:Ivabradine; D001262:Atenolol; D017298:Bisoprolol